Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 12/01 03:59:44 pm
134.725 EUR   +0.65%
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partnerships
DJ
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
MD
11/26MERCK : Partners With Siemens on New Plant
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Darmstadt, Germany Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis

09/10/2020 | 08:10am EST
10 Sep 2020| Darmstadt, Germany
  • Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F
  • Phase II study was facilitated by Avillion as part of an innovative co-development model

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced positive top-line results from a Phase II study of sonelokinab (M1095), an investigational anti-IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F, in patients with moderate to severe chronic plaque-type psoriasis. Currently there are no approved IL-17 A/F nanobodies. The Phase II study was completed through a co-development agreement with Avillion, first announced in 2017.

'This Phase II study was conducted by Avillion as part of an innovative co-development model and we thank them for their partnership and successful completion of this trial with high quality data,' said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck KGaA, Darmstadt, Germany. 'Given the encouraging Phase II results we will explore partnership options to rapidly deliver this promising new therapy to patients living with psoriasis.'

The randomized, double-blind, placebo controlled, multi-centre, Phase IIb study was designed to assess efficacy, safety, and tolerability of sonelokinab in subjects with moderate to severe chronic plaque-type psoriasis. The trial enrolled 313 patients (age 18-75) with chronic plaque psoriasis for at least six months, with an Investigator Global Assessment (IGA) score ≥3, involved body surface area ≥10%, and Psoriasis and Severity Index (PASI) ≥12 at screening and at baseline. Patients were randomized to one of four dose regimens of sonelokinab, or a placebo comparator arm, or a reference arm (secukinumab). The study met its primary endpoint of IGA response of at least 2 points reduction from baseline, and secondary endpoints of PASI with high statistical significance (p

'The Phase II study results for sonelokinab provide valuable insights. The onset of action and potential durable response of sonelokinab in psoriasis patients merits further characterization in a comprehensive Phase III program,' said Kim Papp, MD, PhD, FRCPC, Primary Investigator.

Merck KGaA, Darmstadt, Germany acquired full, exclusive rights to the anti-IL 17 A/F Nanobody® through a global development and commercialization deal with Ablynx (now Ablynx, a Sanofi Company) in 2013.

About sonelokinab (M1095)

The anti-IL-17 A/F Nanobody® sonelokinab is an investigational bi-specific half-life-extended Nanobody that is thought to neutralise both IL-17A and IL-17F with the potential to treat inflammatory diseases, including psoriasis. Currently there are no approved IL-17 A/F nanobodies. Merck KGaA, Darmstadt, Germany acquired full, exclusive rights to the anti-IL 17 A/F Nanobody® through a global development and commercialization deal with Ablynx (now Ablynx, a Sanofi Company) in 2013.

Merck KGaA, Darmstadt, Germanyin Neurology and Immunology

Merck KGaA, Darmstadt, Germany, has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS, with a robust pipeline focusing on discovering new therapies that have the potential to modulate key pathogenic mechanisms in MS. Merck KGaA, Darmstadt, Germany, aims to improve the lives of those living with MS, by addressing areas of unmet medical needs.

The company`s robust immunology pipeline focuses on discovering new therapies that have the potential to modulate key pathogenic mechanisms in chronic diseases such as MS, systemic lupus erythematosus, osteoarthritis and psoriasis.

Disclaimer

Merck KGaA published this content on 10 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2020 12:09:06 UTC


© Publicnow 2020
All news about MERCK KGAA
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partne..
DJ
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
MD
11/26MERCK : Partners With Siemens on New Plant
DJ
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
More news
Financials
Sales 2020 17 381 M 20 980 M 20 980 M
Net income 2020 2 013 M 2 429 M 2 429 M
Net Debt 2020 11 224 M 13 548 M 13 548 M
P/E ratio 2020 28,8x
Yield 2020 1,05%
Capitalization 58 565 M 70 594 M 70 691 M
EV / Sales 2020 4,02x
EV / Sales 2021 3,73x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 134,70 €
Spread / Highest target 25,5%
Spread / Average Target 0,50%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA27.05%69 553
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD90.24%19 173
KYOWA KIRIN CO., LTD.10.18%14 594
BETTA PHARMACEUTICALS CO., LTD.38.95%5 594
YUHAN CORPORATION36.15%3 641
RECIPHARM AB (PUBL)29.21%1 996